NovoCure Limited (NVCR)
USD 31.54
(-1.73%)
USD 31.54
(-1.73%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 355.42 Million USD | -24.21% |
| 2022 | 468.94 Million USD | 27.98% |
| 2021 | 366.41 Million USD | 74.88% |
| 2020 | 209.52 Million USD | 1623.04% |
| 2019 | -13.75 Million USD | -259.11% |
| 2018 | 8.64 Million USD | -53.89% |
| 2017 | 18.75 Million USD | 628.32% |
| 2016 | -3.54 Million USD | 96.32% |
| 2015 | -96.32 Million USD | -68.13% |
| 2014 | -57.29 Million USD | 67.36% |
| 2013 | -175.54 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 141.49 Million USD | -60.19% |
| 2024 Q2 | 506.75 Million USD | 258.14% |
| 2024 Q3 | 469.06 Million USD | -3.27% |
| 2023 Q4 | 355.42 Million USD | -18.33% |
| 2023 Q3 | 435.18 Million USD | 1.09% |
| 2023 Q2 | 430.5 Million USD | 7.54% |
| 2023 Q1 | 400.33 Million USD | -14.63% |
| 2023 FY | 355.42 Million USD | -24.21% |
| 2022 Q2 | 210.2 Million USD | -45.7% |
| 2022 FY | 468.94 Million USD | 27.98% |
| 2022 Q3 | 335.69 Million USD | 59.7% |
| 2022 Q4 | 468.94 Million USD | 39.69% |
| 2022 Q1 | 387.1 Million USD | 5.65% |
| 2021 Q2 | 223.38 Million USD | -13.33% |
| 2021 FY | 366.41 Million USD | 74.88% |
| 2021 Q3 | -116.97 Million USD | -152.36% |
| 2021 Q4 | 366.41 Million USD | 413.25% |
| 2021 Q1 | 257.74 Million USD | 23.01% |
| 2020 Q2 | -33.6 Million USD | -75.23% |
| 2020 FY | 209.52 Million USD | 1623.04% |
| 2020 Q4 | 209.52 Million USD | 194.64% |
| 2020 Q3 | -221.38 Million USD | -558.7% |
| 2020 Q1 | -19.18 Million USD | -39.42% |
| 2019 Q4 | -13.75 Million USD | 70.9% |
| 2019 FY | -13.75 Million USD | -259.11% |
| 2019 Q3 | -47.28 Million USD | -146.95% |
| 2019 Q2 | -19.14 Million USD | -332.0% |
| 2019 Q1 | 8.25 Million USD | -4.55% |
| 2018 Q4 | 8.64 Million USD | -67.09% |
| 2018 FY | 8.64 Million USD | -53.89% |
| 2018 Q1 | 37.55 Million USD | 100.3% |
| 2018 Q2 | 34.73 Million USD | -7.5% |
| 2018 Q3 | 26.27 Million USD | -24.37% |
| 2017 Q4 | 18.75 Million USD | 25.46% |
| 2017 FY | 18.75 Million USD | 628.32% |
| 2017 Q1 | 11.9 Million USD | 435.45% |
| 2017 Q2 | 16.57 Million USD | 39.23% |
| 2017 Q3 | 14.94 Million USD | -9.83% |
| 2016 FY | -3.54 Million USD | 96.32% |
| 2016 Q4 | -3.54 Million USD | 82.12% |
| 2016 Q3 | -19.85 Million USD | 65.52% |
| 2016 Q2 | -57.57 Million USD | 37.91% |
| 2016 Q1 | -92.73 Million USD | 3.72% |
| 2015 Q2 | -81.96 Million USD | -64.94% |
| 2015 FY | -96.32 Million USD | -68.13% |
| 2015 Q1 | -49.69 Million USD | 13.26% |
| 2015 Q4 | -96.32 Million USD | -12.31% |
| 2015 Q3 | -85.77 Million USD | -4.64% |
| 2014 Q1 | 175.89 Million USD | 0.0% |
| 2014 FY | -57.29 Million USD | 67.36% |
| 2014 Q4 | -57.29 Million USD | 0.0% |
| 2013 FY | -175.54 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 2.58 Million USD | -13670.67% |
| AngioDynamics, Inc. | -70.14 Million USD | 606.716% |
| AtriCure, Inc. | -9.81 Million USD | 3720.833% |
| Avinger, Inc. | 10.12 Million USD | -3412.065% |
| Azenta, Inc. | -618.47 Million USD | 157.467% |
| BioLife Solutions, Inc. | 7.25 Million USD | -4800.331% |
| The Cooper Companies, Inc. | 2.44 Billion USD | 85.484% |
| Daxor Corporation | 755.65 Thousand USD | -46934.575% |
| Ekso Bionics Holdings, Inc. | -1.47 Million USD | 24278.299% |
| Femasys Inc. | -15.01 Million USD | 2467.075% |
| GlucoTrack, Inc. | -4.29 Million USD | 8373.301% |
| Harvard Bioscience, Inc. | 38.49 Million USD | -823.411% |
| Hologic, Inc. | 374.4 Million USD | 5.069% |
| ICU Medical, Inc. | 1.45 Billion USD | 75.497% |
| Intuitive Surgical, Inc. | -2.66 Billion USD | 113.36% |
| KORU Medical Systems, Inc. | -7.03 Million USD | 5150.66% |
| LeMaitre Vascular, Inc. | -5.17 Million USD | 6969.366% |
| Innovative Eyewear, Inc. | -4.28 Million USD | 8389.805% |
| Innovative Eyewear, Inc. | -4.28 Million USD | 8389.805% |
| Masimo Corporation | 804 Million USD | 55.793% |
| Microbot Medical Inc. | -2.28 Million USD | 15647.725% |
| Meihua International Medical Technologies Co., Ltd. | -9.59 Million USD | 3803.944% |
| Merit Medical Systems, Inc. | 302.22 Million USD | -17.602% |
| Nephros, Inc. | -2.47 Million USD | 14483.691% |
| NEXGEL, Inc. | 98 Thousand USD | -362574.49% |
| NEXGEL, Inc. | 98 Thousand USD | -362574.49% |
| Singular Genomics Systems, Inc. | 59.05 Million USD | -501.847% |
| OraSure Technologies, Inc. | -276.9 Million USD | 228.356% |
| Pro-Dex, Inc. | 10.91 Million USD | -3155.964% |
| Pulse Biosciences, Inc. | -35.22 Million USD | 1109.117% |
| Predictive Oncology Inc. | -5.87 Million USD | 6152.969% |
| Precision Optics Corporation, Inc. | 3.02 Million USD | -11633.23% |
| QuidelOrtho Corporation | 2.49 Billion USD | 85.756% |
| Repligen Corporation | -39.51 Million USD | 999.367% |
| Sanara MedTech Inc. | 6.64 Million USD | -5248.784% |
| STAAR Surgical Company | -147.2 Million USD | 341.448% |
| Sharps Technology, Inc. | -3.01 Million USD | 11896.61% |
| Utah Medical Products, Inc. | -92.52 Million USD | 484.131% |
| DENTSPLY SIRONA Inc. | 1.96 Billion USD | 81.912% |
| Jin Medical International Ltd. | -2.81 Million USD | 12719.208% |